At #ESMO26, Alberto Briganti presented the PROTEUS substudy, reporting improved EFS with perioperative apalutamide + ADT (HR 0.38).

Nicholas van As discussed key limitations and concluded that longer follow-up is needed before changing clinical practice.

#ProstateCancer